📊 ZEOX Key Takeaways
Is Zeo ScientifiX, Inc. (ZEOX) a Good Investment?
Zeo ScientifiX faces a critical solvency crisis with negative stockholders' equity of -$383K and a severe liquidity crisis (current ratio 0.70x), indicating liabilities exceed assets. With operating cash burn of -$471K annually against only $1.0M in cash reserves, the company has approximately 2 years of runway while failing to achieve profitability on $1.4M revenue. While the 80.6% gross margin demonstrates strong unit economics, operating losses of -$878K reveal unsustainable overhead that must be cut dramatically or revenue must scale 5-10x for viability.
Why Buy Zeo ScientifiX, Inc. Stock? ZEOX Key Strengths
- Revenue growth of 12.5% YoY demonstrates market traction
- Gross margin of 80.6% indicates healthy unit economics and strong product pricing power
- $1.0M cash on hand provides short-term liquidity cushion
ZEOX Stock Risks: Zeo ScientifiX, Inc. Investment Risks
- Negative stockholders' equity of -$383K indicates technical insolvency and accounting distress
- Current ratio of 0.70x and quick ratio of 0.52x signal inability to meet near-term obligations
- Operating cash burn of -$471K annually is unsustainable with ~$1M cash (2-year runway at current burn)
- Operating margin of -60.7% with $878K operating loss indicates overhead costs are 63x revenue
- No insider buying activity in past 90 days suggests management lacks confidence
Key Metrics to Watch
- Quarterly cash balance and burn rate trend
- Operating expense reduction and path to operating break-even
- Revenue growth rate and absolute revenue level required for profitability
- Ability to raise capital or secure financing before cash depletion
Zeo ScientifiX, Inc. (ZEOX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
ZEOX Profit Margin, ROE & Profitability Analysis
ZEOX vs Healthcare Sector: How Zeo ScientifiX, Inc. Compares
How Zeo ScientifiX, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Zeo ScientifiX, Inc. Stock Overvalued? ZEOX Valuation Analysis 2026
Based on fundamental analysis, Zeo ScientifiX, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Zeo ScientifiX, Inc. Balance Sheet: ZEOX Debt, Cash & Liquidity
ZEOX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Zeo ScientifiX, Inc.'s revenue has grown significantly by 70% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.99 indicates the company is currently unprofitable.
ZEOX Revenue Growth, EPS Growth & YoY Performance
ZEOX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $1.1M | -$852.0K | $-0.12 |
| Q3 2025 | $1.1M | -$1.0M | $-0.16 |
| Q2 2025 | $1.1M | -$1.4M | $-0.22 |
| Q1 2025 | $1.1M | -$1.0M | $-0.17 |
| Q3 2024 | $1.1M | -$1.0M | $-0.16 |
| Q2 2024 | $845.0K | -$1.4M | $-0.23 |
| Q1 2024 | $1.1M | -$1.0M | $-0.17 |
| Q3 2023 | $1.2M | -$1.6M | $0.00 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Zeo ScientifiX, Inc. Dividends, Buybacks & Capital Allocation
ZEOX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Zeo ScientifiX, Inc. (CIK: 0001557376)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ZEOX
What is the AI rating for ZEOX?
Zeo ScientifiX, Inc. (ZEOX) has an AI rating of STRONG SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are ZEOX's key strengths?
Claude: Revenue growth of 12.5% YoY demonstrates market traction. Gross margin of 80.6% indicates healthy unit economics and strong product pricing power.
What are the risks of investing in ZEOX?
Claude: Negative stockholders' equity of -$383K indicates technical insolvency and accounting distress. Current ratio of 0.70x and quick ratio of 0.52x signal inability to meet near-term obligations.
What is ZEOX's revenue and growth?
Zeo ScientifiX, Inc. reported revenue of $1.4M.
Does ZEOX pay dividends?
Zeo ScientifiX, Inc. does not currently pay dividends.
Where can I find ZEOX SEC filings?
Official SEC filings for Zeo ScientifiX, Inc. (CIK: 0001557376) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ZEOX's EPS?
Zeo ScientifiX, Inc. has a diluted EPS of $-0.12.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is ZEOX a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Zeo ScientifiX, Inc. has a STRONG SELL rating with 92% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is ZEOX stock overvalued or undervalued?
Valuation metrics for ZEOX: ROE of N/A (sector avg: 15%), net margin of -58.9% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy ZEOX stock in 2026?
Our dual AI analysis gives Zeo ScientifiX, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ZEOX's free cash flow?
Zeo ScientifiX, Inc.'s operating cash flow is $-471.0K, with capital expenditures of $14.0K. FCF margin is -33.5%.
How does ZEOX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -58.9% (avg: 12%), ROE N/A (avg: 15%), current ratio 0.70 (avg: 2).